Education
About Us
Working with TipRanks
Follow Us
Cybin (HELP)
NASDAQ:HELP
HELP Stock Chart & Stats
$7.13
-$0.06(-0.78%)
At close: 4:00 PM EST
$7.13
-$0.06(-0.78%)
Day’s Range― - ―
52-Week Range$4.81 - $10.72
Previous Close$7.77
Volume369.09K
Average Volume (3M)N/A
Market Cap
$1.42M
Enterprise Value$0.00
Total Cash (Recent Filing)$116.53M
Total Debt (Recent Filing)$40.19M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Feb 17, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding49,894,130
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)7.14
Price to Sales (P/S)0.00
P/FCF Ratio-16.39
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$45.00Price Target Upside531.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HELP FAQ
What was Cybin’s price range in the past 12 months?
Cybin lowest stock price was $4.81 and its highest was $10.72 in the past 12 months.
What is Cybin’s market cap?
Cybin’s market cap is $1.42M.
When is Cybin’s upcoming earnings report date?
Cybin’s upcoming earnings report date is Feb 17, 2026 which is in 18 days.
How were Cybin’s earnings last quarter?
Cybin released its earnings results on Nov 13, 2025. The company reported -$1.437 earnings per share for the quarter, missing the consensus estimate of -$1.075 by -$0.362.
Is Cybin overvalued?
According to Wall Street analysts Cybin’s price is currently Undervalued.
Does Cybin pay dividends?
Cybin does not currently pay dividends.
What is Cybin’s EPS estimate?
Cybin’s EPS estimate is -0.6.
How many shares outstanding does Cybin have?
Cybin has 49,894,130 shares outstanding.
What happened to Cybin’s price movement after its last earnings report?
Cybin reported an EPS of -$1.437 in its last earnings report, missing expectations of -$1.075. Following the earnings report the stock price went down -8.05%.
Which hedge fund is a major shareholder of Cybin?
Currently, no hedge funds are holding shares in HELP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cybin
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
HELP Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company making significant progress in advancing its clinical programs and strengthening its financial position, despite facing challenges such as leadership transition and increased expenses. The overall sentiment is balanced, with solid achievements in clinical and operational fronts but offset by financial and leadership concerns.View all HELP earnings summariesHELP Stock 12 Month Forecast
Average Price Target
$45.00
▲(531.14% Upside)
Entheon Biomedical
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Nirvana Life Sciences Inc
―
Mindbio Therapeutics Corp.
―
Ownership Overview
1.38% Insiders
―
Mutual Funds
0.38% Other Institutional Investors
98.03% Public Companies and Individual Investors
Options Prices
Currently, No data available
---